第六批国家组织高值医用耗材集采开标 共440个产品中选

Core Insights - The sixth batch of centralized procurement for high-value medical consumables was held in Tianjin, resulting in the selection of 440 products from 202 companies out of 496 bids from 227 companies, indicating a diverse supply of products to meet clinical needs [1][2] Group 1: Procurement Details - The procurement includes 12 types of medical consumables, specifically drug-coated balloons and urological intervention materials, which are crucial for treating vascular and urinary conditions [1] - All 42 products from 32 companies in the drug-coated balloon category were selected, ensuring a high match with clinical usage while reducing patient costs [1] - In the urological intervention category, 398 products from 170 companies were selected, addressing a previously unaddressed area in centralized procurement [1] Group 2: Policy Implementation - The procurement aligns with the central government's policy to optimize procurement processes, emphasizing stability in clinical use, quality assurance, and prevention of price undercutting [2] - Group competition was implemented to ensure continuity in clinical usage, with products selected based on demand and supply capabilities [2] - The selection rules were optimized to prevent price undercutting, with a benchmark set at 65% of the average price when the lowest bid is excessively low, impacting 8 out of 20 competitive groups [2] Group 3: Historical Context - Since 2020, the healthcare insurance department has conducted six batches of centralized procurement, successfully acquiring 142 types of medical consumables across various clinical fields, including cardiology, orthopedics, and urology [2]